IMBRUVICA® is the only BTKi approved for one tablet, once a day in 1L CLL*

Once-daily dosing to fit your patient’s routine1

Continue IMBRUVICA® treatment until disease progression or unacceptable toxicity.

  • Administer IMBRUVICA® at approximately the same time each day with a glass of water
  • Swallow tablets or capsule whole. Do not open, break, or chew the capsules. Do not cut, crush, or chew the tablets
  • If a dose of IMBRUVICA® is not taken at the scheduled time, it can be taken as soon as possible on the same day with a return to the normal schedule the following day. Do not take extra doses of IMBRUVICA® to make up for the missed dose

Other BTKi treatments have dose modifications for ARs and drug-drug interactions that can result in one-tablet, once-daily dosing.

Agents administered in combination with IMBRUVICA® require infusion. When administering IMBRUVICA® in combination with rituximab or obinutuzumab, consider administering IMBRUVICA® prior to rituximab or obinutuzumab when given the same day.

I liked the idea that it was an oral medication that I could take once a day.”


CLL Patient

Once-daily dosing is necessary to ensure inhibition of BTK enzymatic activity1

IMBRUVICA® occupancy at the  BTK active site was observed for up to 24 hours with once-daily dosing^1IMBRUVICA® occupancy at the  BTK active site was observed for up to 24 hours with once-daily dosing^1

Discontinuation and dose reduction rates in the CLL/SLL registration studies1

The data below are pooled from 5 randomized controlled clinical trials (RESONATE™, RESONATE™-2, HELIOS, iLLUMINATE™, and E1912) and 1 single-arm, open-label clinical trial (Study 1102) in patients with CLL/SLL (N=2,016 total and n=1,133 patients exposed to IMBRUVICA®)

  • 4% to 10% of patients discontinued due to ARs
    • ARs leading to discontinuation included pneumonia, hemorrhage, atrial fibrillation, neutropenia, arthralgia, rash, and thrombocytopenia
  • Approximately 9% of patients had a dose reduction due to ARs
  • Patients requiring a dose reduction can exchange their unused tablets for the same number of tablets at the reduced dose strength
  • Your patient can receive their new dose before returning their unused tablets
  • In this safety-based returns program, there will be no additional cost to the patient for any tablets provided at the reduced dose strength

Patients must enroll in the program to apply. To be eligible for participation in the IMBRUVICA® By Your Side Dose Exchange Program, patients must have remaining pills from a current prescription for an FDA-approved indication for IMBRUVICA® and must return their remaining pills.


1L=first-line, ARs=adverse reactions, BR=bendamustine + rituximab, BTK=Bruton's tyrosine kinase, BTKi=Bruton’s tyrosine kinase inhibitor, CLL=chronic lymphocytic leukemia, SLL=small lymphocytic lymphoma.


1IMBRUVICA® (ibrutinib) Prescribing Information.